| Name | Title | Contact Details |
|---|
At LAVA, we are focused on applying our expertise in gamma-delta T-cell engagers (TCEs) to transform cancer therapy. We refer to our compounds as gamma-delta bispecific T-cell engagers, or gamma-delta bsTCEs. Our platform generates therapeutics that specifically activate a unique and relatively abundant effector gamma-delta T-cell subset called Vγ9Vδ2 (Vgamma9-Vdelta2) T-cells that have the ability to trigger activity of immune cells of both the innate and adaptive immune system. Our gamma-delta bsTCEs have demonstrated superior efficacy and safety profiles compared to other bsTCE approaches in preclinical studies and show preferential activity against tumor cells thereby potentially limiting toxicity in healthy tissue. To date, we are the only company developing bispecific gamma-delta T-cell engaging antibodies for the treatment of cancer. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor specific antigen CD1d, which can be overexpressed in multiple myeloma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML), among other tumor types. LAVA-051 will enter a Phase I/IIa study in 1Q21.
Oxford Finance Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Skyhawk Therapeutics is a drug discovery and development company focused on revolutionizing disease treatment with small molecules that correct RNA expression.
Renaissance RX is on the forefront of the new era of personalized medicine. The laboratory provides Pharmacogenetic Testing and Advanced Toxicology to give doctors unique insight into each individual patient with the most accurate and actionable information. The results are healthier patients and more successful medical practices. To compliment lab services and help ensure drug adherence, Renaissance RX offers access to its online medication portal and the Virtual PharmD Intelligence Engine.
Gameto is a biotechnology company that uses cell engineering to develop novel therapeutics for the diseases of the female reproductive system.